Form 4 for CLDX Celldex Therapeutics, Inc.

Accepted 2024-02-15 00:00:00 ET · period of report 2024-02-13 · accession 0001415889-24-003891 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
DM	2024-02-15	2024-02-13	CLDX	Jimenez Freddy A.	SVP, GC	M - OptEx	$3.86	+24.2K	25.9K	+1,375%	+$93.2K
DM	2024-02-15	2024-02-13	CLDX	Jimenez Freddy A.	SVP, GC	M - OptEx	$0.00	-24.2K	0	-100%	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2024-02-13	M	A	4,166	$9.02	5,924	D	—	—	(F1) On February 8, 2019, Celldex Therapeutics, Inc. effected a 1-for-15 reverse stock split of its common stock (the "Reverse Stock Split"). This option was previously reported as covering 62,500 shares at an exercise price of $0.6011 per share, but has been adjusted to reflect the Reverse Stock Split. (F2) Includes 1,328 shares of common stock acquired under the Celldex Therapeutics, Inc. 2004 Employee Stock Purchase Plan.
2	Common	Common Stock	2024-02-13	M	A	20,000	$2.78	25,924	D	—	—
3	Derivative	Incentive Stock Option (Right to Buy)	2024-02-13	M	D	20,000	$0.00	0	D	$2.78 · — to 2029-06-19	20,000 Common Stock	(F4) As of June 19, 2023, the option is fully vested.
4	Derivative	Incentive Stock Option (Right to Buy)	2024-02-13	M	D	4,166	$0.00	0	D	$9.02 · — to 2028-06-13	4,166 Common Stock	(F1) On February 8, 2019, Celldex Therapeutics, Inc. effected a 1-for-15 reverse stock split of its common stock (the "Reverse Stock Split"). This option was previously reported as covering 62,500 shares at an exercise price of $0.6011 per share, but has been adjusted to reflect the Reverse Stock Split. (F3) As of June 13, 2022, the option is fully vested.